GlassScriptPhysician profile
Jacob Ryan Gray
NPI 1043917842
$2,155.36
in general payments reported to CMS, 2019-2025
15 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $610.16 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $388.79 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $350.75 | 2025 | |
| Corium, LLC | $159.65 | 2025 | Azstarys |
| Neurocrine Biosciences, INC. | $122.87 | 2025 | |
| Alkermes, INC. | $90.16 | 2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $85.88 | 2025 | Fanapt |
| Lundbeck LLC | $67.20 | 2025 | Abilify Maintena |
| Janssen Pharmaceuticals, INC | $62.87 | 2025 | Spravato |
| Tris Pharma INC | $61.78 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $50.21 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $44.06 | 2025 | Trintellix |
| Sage Therapeutics, LLC | $22.81 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $22.81 | 2025 | Qelbree |
| Bausch Health US, LLC | $15.36 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.